| Literature DB >> 28530888 |
Emeli Månsson1,2, Bengt Hellmark3, Marc Stegger4, Paal Skytt Andersen4, Martin Sundqvist3, Bo Söderquist2.
Abstract
PURPOSE: The aim of the study was to characterize clinical and environmental Staphylococcus pettenkoferi isolates with regard to genomic diversity and antibiotic susceptibility pattern. Repetitive-sequence-based PCR and core genome phylogenetic analysis of whole-genome sequencing (WGS) data verified the presence of distinct clades comprising closely related S. pettenkoferi isolates from different geographical locations and origins.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28530888 PMCID: PMC5817227 DOI: 10.1099/jmm.0.000472
Source DB: PubMed Journal: J Med Microbiol ISSN: 0022-2615 Impact factor: 2.472
Characteristics of S. pettenkoferi isolates (n=25) obtained from blood cultures and air sampling in operating theatres during prosthetic joint surgery
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; TKA, total knee arthroplasty; THA, total hip arthroplasty. –, data not available.
| Isolate ID | Year | Continent | Origin | Positive bottles/bottles cultured | Nosocomial | Clinical data | Age | Sex |
|---|---|---|---|---|---|---|---|---|
| Vaxjo_1 | 2011 | Europe | Blood culture | 1/4 | No | Suspected sepsis | 82 | F |
| Vaxjo_2 | 2011 | Europe | Blood culture | 1/4 | No | Elevated CRP | 90 | F |
| Vaxjo_3 | 2012 | Europe | Blood culture | 1/4 | No | Elevated CRP, fever | 56 | M |
| Vaxjo_4 | 2012 | Europe | Blood culture | 1/4 | Yes | Elevated CRP, shortness of breath | 89 | F |
| Vaxjo_5 | 2012 | Europe | Blood culture | 1/4 | No | Suspected aspiration pneumonia | 72 | M |
| Vaxjo_6 | 2012 | Europe | Blood culture | 1/4 | No | Fever, COPD | 87 | F |
| Vaxjo_7 | 2013 | Europe | Blood culture | 1/4 | No | Suspected sepsis | 60 | M |
| Vaxjo_8 | 2013 | Europe | Blood culture | – | – | – | – | – |
| Vaxjo_9 | 2013 | Europe | Blood culture | 2/4 | No | Elevated CRP | 85 | M |
| Vaxjo_10 | 2013 | Europe | Blood culture | 1/4 | Yes | Immunocompromised, fever | 65 | M |
| Vaxjo_11 | 2013 | Europe | Blood culture | 1/4 | Yes | Fever, elevated CRP | 50 | M |
| Vaxjo_12 | 2013 | Europe | Blood culture | 1/4 | No | Fever | 16 | F |
| Vaxjo_13 | 2013 | Europe | Blood culture | 1/4 | Yes | Elevated CRP | 83 | F |
| Orebro_14 | 2014 | Europe | Blood culture | 2/4 | No | Immunocompromised, fever | 65 | M |
| JMI_15 | 2006 | North America | Blood culture | – | Yes | – | 61 | M |
| JMI_16 | 2008 | Europe | Blood culture | – | No | – | – | – |
| Vasteras_17 : 1–8 | 2011 | Europe | Peri-operative air sampling | TKA | 120 | |||
| Vasteras_18 : 1 | 2011 | Europe | Peri-operative air sampling | THA | 15 | |||
Fig. 1.DiversiLab (DL) rep-PCR profiles of 26 S. pettenkoferi isolates. (a) Profiles and corresponding dendrogram obtained using the Kullback–Leibner method for correlation analysis. The similarity line (95 %) is presented as a light grey dotted vertical line. Each colour represents a single pattern (indistinguishable profiles). Isolates deemed clinically significant are marked with an asterisk. (b) Scatter plot of 26 S. pettenkoferi isolates. Each isolate is represented by its number corresponding to the DL profile, as presented in (a) ('key'). Colour represents origin of isolates [blue sampling (A); green, blood culture (BC); pinkreference strain (RS); pattern (P)].
Fig. 2.Examples of graphs of isolates belonging to clade A and B. Clade A is represented by the clinically significant isolate Vaxjo_9 and clade B is represented by the environmental isolate Vasteras 17 : 3.
Fig. 3.Midpoint-rooted maximum-likelihood approximation using FastTree 2.1.5 on the 157 438 core SNP within 26 isolates of S. pettenkoferi aligned with three available S. pettenkoferi draft genomes. Isolates deemed clinically significant are marked with an asterisk. Rep-PCR clade is presented to the right of isolate ID. Colour represents origin of isolates (blue, air sampling; green, blood culture; pink, reference strain). Scale bar indicates the number of SNP distances. Range of intra-clade SNP distances: clade A 11–1872, clade B 0–672.
Antibiotic susceptibility patterns of S. pettenkoferi isolates (n=25)
Antimicrobial susceptibility testing according to EUCAST guidelines. S, susceptible (white); R, resistant (light grey).
| Isolate ID | Year | Cefoxitin | Fusidic acid | Clindamycin | Erythromycin | Gentamicin | Rifampicin | TMP/SMX | Norfloxacin | |
|---|---|---|---|---|---|---|---|---|---|---|
| Vaxjo_1 | 2011 | S | S | S | S | S | S | S | ||
| Vaxjo_2 | 2011 | S | S | S | S | S | S | S | S | |
| Vaxjo_3 | 2012 | S | R | S | S | S | S | S | S | |
| Vaxjo_4 | 2012 | S | S | S | S | S | S | S | S | |
| Vaxjo_5 | 2012 | S | S | S | S | S | S | R | S | |
| Vaxjo_6 | 2012 | R* | R | R | R | S | S | S | R | |
| Vaxjo_7 | 2013 | S | S | S | R | S | S | S | S | |
| Vaxjo_8 | 2013 | S | R | S | S | S | S | S | S | |
| Vaxjo_9 | 2013 | R* | S | R | R | S | S | S | R | |
| Vaxjo_10 | 2013 | S | S | S | S | S | S | S | S | |
| Vaxjo_11 | 2013 | S | S | S | S | S | S | S | S | |
| Vaxjo_12 | 2013 | S | S | S | S | S | S | S | S | |
| Vaxjo_13 | 2013 | S | S | S | S | S | S | S | S | |
| Orebro_14 | 2014 | S | S | S | S | S | S | S | S | |
| JMI_15 | 2006 | S | S | S | S | S | S | S | S | |
| JMI_16 | 2008 | S | S | S | S | S | S | S | S | |
| Vasteras_17 : 1 | 2011 | S | R | S | S | S | S | S | S | |
| Vasteras_17 : 2 | 2011 | S | R | R | R | S | S | S | S | |
| Vasteras_17 : 3 | 2011 | S | S | S | S | S | S | S | S | |
| Vasteras_17 : 4 | 2011 | S | S | S | S | S | S | S | S | |
| Vasteras_17 : 5 | 2011 | S | S | S | S | S | S | S | S | |
| Vasteras_17 : 6 | 2011 | S | S | S | S | S | S | S | S | |
| Vasteras_17 : 7 | 2011 | S | S | S | S | S | S | S | S | |
| Vasteras_17 : 8 | 2011 | S | S | S | S | S | S | S | S | |
| Vasteras_18 : 1 | 2011 | S | S | S | S | S | S | S | S | |
*Isolate mecA-positive.